|
|
|
| The New Economics of Biologics: Breaking the $50/g Barrier — Now | When does process intensification become the stronger economic choice for mAb manufacturing? The answer depends on production volume, titer, facility utilization, and process configuration. In our new report, modeling results show how different manufacturing scenarios influence cost of goods — and where intensified single-use and continuous approaches can support costs below $50/g. Read the report to explore the economics behind the next generation of biologics manufacturing. |
|
|
|
Webinar | MilliporeSigma | Explore how non-animal methods, including next generation sequencing, are advancing biologics safety testing through the 3Rs while supporting faster adventitious virus testing and more. |
|
|
|
Video | Thermo Fisher Scientific | Uniform bubble size and consistent mass transfer across scales through drilled-hole sparge technology improve cell culture processes. |
|
|
|
Webinar | ATUM | Discover the application of a platform in creating CHO cell lines for manufacturing multi-chain biologics, emphasizing the uniformity of the pools in terms of titer and rapid selection. |
|
|
|
Video | Bioprocess Online | In this episode of “Better Biopharma,” host Tyler Menichiello is joined by Kat Kozyrytska, a technology advisor and portfolio strategy leader. |
|
|
|
Webinar | Miltenyi Biotec | Advances in TIL therapy are driving a shift from manual processes to streamlined, automated manufacturing. See how improved workflows and early clinical results are shaping cancer treatments. |
|
|
|
Webinar | MasterControl, Inc. | Responsible AI adoption depends on clear governance, expert oversight, and transparent deployment. Learn how low-risk strategies can help teams innovate while maintaining compliance and trust. |
|
|
| Connect With Bioprocess Online: |
|
|
|
